Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with recurrent epithelial ovarian carcinoma (EOC) after complete response (CR) to 1st-line platinum (Pt)-based ct: Primary analysis of a phase 2, open-label, randomized, multicenter trial.
/in Dendritic Cells, International Publications, Ovarian CancerPersonalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
/in Dendritic Cells, International Publications, Ovarian CancerMtHsp70-CLIC1-pulsed dendritic cells enhance the immune response against ovarian cancer
/in Dendritic Cells, International Publications, Ovarian CancerNewcastle Disease Virus Establishes Persistent Infection in Tumor Cells : Contribution of the Cleavage Site of Fusion Protein and Second Sialic Acid Binding Site of Hemagglutinin-Neuraminidase
/in International Publications, Newcastle Disease Virus, Ovarian CancerInfluence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells
/in Dendritic Cells, International Publications, Ovarian CancerCancer Vaccines in Ovarian Cancer: How Can We Improve?
/in Dendritic Cells, International Publications, Ovarian CancerA study of mature alpha-DC-1 vaccine to induce immune responses in ovarian cancer.
/in Dendritic Cells, International Publications, Ovarian CancerCellular immunotherapy in ovarian cancer: Targeting the stem of recurrence
/in Dendritic Cells, International Publications, Ovarian Cancer[The effect of immunotherapy and hyperthermia on advanced or recurrent ovarian and uterine cancer – 229 clinical cases]
/in Endometrial Cancer, International Publications, Ovarian Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer